Marcos J. Guerrero-Munoz, Ph.D.

Dr. Marcos Guerrero-Munoz

B.S., Biological and Pharmaceutical Chemistry at Autonomous University of Nuevo Leon (Mexico)
MSc., Molecular Biology Autonomous University of Nuevo Leon (Mexico)
Ph.D. in Morphology Autonomous University of Nuevo Leon (Mexico)
Postdoctoral Training: University of Texas Medical Branch and Baylor College of Medicine 

Phone: (757) 728-6047
E-mail: marcos.guerreromunoz@hamptonu.edu

Dr. Marcos J. Guerrero-Munoz is native of Nuevo Leon, Mexico. He obtained a B.S. in biological and pharmaceutical chemistry at Autonomous University of Nuevo Leon (Mexico) where he also received a MSc. in molecular biology and Ph.D. in morphology. 

During his Ph.D. degree and postdoctoral training (University of Texas Medical Branch and Baylor College of Medicine), he was focused on the study of intrinsically disordered proteins (IDP) related to Parkinson’s disease and Alzheimer’s disease among others. In January 2016, he joined at Hampton-Brandesis’s (PREM) Partnership for Research and Education in Materials as a Path to Professorship (PTP). His research is focused in the study of structural features of IDP in health and degenerative diseases such as Alzheimer’s disease and type 2 diabetes mellitus.

Honors

  • 2012 -2017 Member of National Researchers System of Mexico in the category of Biology and Chemistry.
  • 2013  Excellence in Postdoctoral Research for Neuroscience research. 17th Annual forum on Aging. November 12, 2013. Galveston, Texas.
  • 2010  Postdoctoral Training Scholarship awarded by University of Texas Medical Branch, Galveston, Texas.
  • 2004  PhD Scholarship awarded by National Council of Science and Technology (CONACYT), Mexico.
  • 1999  Master of Science Scholarship awarded by National Council of Science and Technology (CONACYT), Mexico. 

Selected Recent Publications

  1. Guerrero-Muñoz MJ, Gerson JE and Castillo-Carranza DL. Tau oligomers: the toxic player at synapses in Alzheimer’s disease. Front Cell Neurosci. 2015 Dec 2;9:464. doi: 10.3389/fncel.2015.00464. eCollection 2015. Review. PubMed PMID: 26696824;PubMed Central PMCID: PMC4667007.
  2. Lasagna-Reeves CA, Rousseaux MW, Guerrero-Muñoz MJ, Vilanova-Velez L, Park J,See L, Jafar-Nejad P, Richman R, Orr HT, Kayed R, Zoghbi HY. Ataxin-1 oligomers induce local spread of pathology and decreasing them by passive immunization slows Spinocerebellar ataxia type 1 phenotypes. Elife. 2015 Dec 17;4. pii:e10891. doi: 10.7554/eLife.10891. [Epub ahead of print] PubMed PMID: 26673892. 
  3. Bodani RU, Sengupta U, Castillo-Carranza DL, Guerrero-Muñoz MJ, Gerson JE,Rudra J, Kayed R. Antibody against Small Aggregated Peptide Specifically Recognizes Toxic Aβ-42 Oligomers in Alzheimer's Disease. ACS Chem Neurosci. 2015 Dec 16;6(12):1981-9. doi: 10.1021/acschemneuro.5b00231. Epub 2015 Oct 8. PubMed PMID: 26448453. 
  4. Lasagna-Reeves CA, Rousseaux MW, Guerrero-Muñoz MJ, Park J, Jafar-Nejad P, Richman R, Lu N, Sengupta U, Litvinchuk A, Orr HT, Kayed R, Zoghbi HY. A native interactor scaffolds and stabilizes toxic ATAXIN-1 oligomers in SCA1. Elife. 2015 May 19;4. doi: 10.7554/eLife.07558. PubMed PMID: 25988806; PubMed Central PMCID: PMC4462648. 
  5. Castillo-Carranza DL, Guerrero-Munoz MJ, Sengupta U, Hernandez C, Barret A, Dineley KT, Kayed R. Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an AD mouse model. J Neurosci. 2015 Mar 25;35(12):4857-68. doi: 10.1523/JNEUROSCI.4989-14.2015. PubMed PMID: 25810517. 
  6. Sengupta U, Guerrero-Munoz M, Castillo-Carranza DL, Krishnamurthy S, Paulucci-Holthauzen A, Sengupta U, Lasagna-Reeves CA, Kayed R. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. Biol Psychiatry. 2015 Jan 9. pii: S0006-3223(15)00003-7. doi:10.1016/j.biopsych.2014.12.019. PubMed PMID: 25676491. 
  7. Guerrero-Muñoz MJ, Castillo-Carranza DL, Krishnamurthy S, Paulucci-Holthauzen AA, Sengupta U, Lasagna-Reeves CA, Ahmad Y, Jackson GR, Kayed R. Amyloid-β oligomers as a template for secondary amyloidosis in Alzheimer's disease. Neurobiol Dis. 2014 Aug 15;71C:14-23. doi: 10.1016/j.nbd.2014.08.008. 
  8. Gerson JE, Sengupta U, Lasagna-Reeves CA, Guerrero-Muñoz MJ, Troncoso J, Kayed R. Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol Commun. 2014 Jun 14;2(1):73. doi: 10.1186/2051-5960-2-73. PubMed PMID: 24927818. 
  9. Lasagna-Reeves CA, Sengupta U, Castillo-Carranza D, Gerson JE, Guerrero-Munoz M, Troncoso JC, Jackson GR, Kayed R. The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes. Acta Neuropathol Commun. 2014 May 29;2(1):56. doi: 10.1186/2051-5960-2-56. PubMed PMID: 24887264. 
  10. Castillo-Carranza DL, Sengupta U, Guerrero-Muñoz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, Estes DM, Barrett AD, Dineley KT, Jackson GR, Kayed R. Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles. J Neurosci. 2014 Mar 19;34(12):4260-72. Doi: 10.1523/JNEUROSCI.3192-13.2014. PubMed PMID:24647946. 
  11. Castillo-Carranza DL, Gerson JE, Sengupta U, Guerrero-Muñoz MJ, Lasagna-Reeves CA, Kayed R. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. J Alzheimers Dis. 2014;40 Suppl 1:S97-S111. doi: 10.3233/JAD-132477. PubMed PMID: 24603946. 
  12. Guerrero-Muñoz MJ, Castillo-Carranza DL, Kayed R. Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. Biochem Pharmacol. 2014 Jan 6. Doi: 10.1016/j.bcp.2013.12.023. 
  13. Castillo-Carranza DL, Guerrero-Muñoz MJ, Kayed R. Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target? ImmunoTargets and Therapy. Dec 2013. DOI: http://dx.doi.org/10.2147/ITT.S40131. 
  14. Guerrero-Muñoz MJ, Castillo-Carranza DL, Sengupta U, White MA, Kayed R. Design of Metastable β-Sheet Oligomers from Natively Unstructured Peptide.ACS Chem Neurosci. 2013 Dec 18. doi: 10.1021/cn4001395. 
  15. Kim HY, Sengupta U, Shao P, Guerrero-Muñoz MJ, Kayed R, Bai M. Alzheimer's disease imaging with a novel Tau targeted near infrared ratiometric probe. Am J Nucl Med Mol Imaging. 2013;3(2):102-17. Epub 2013 Mar 8. PubMed PMID: 23526074; PubMed Central PMCID: PMC3601471. 
  16. Lasagna-Reeves CA, Clos AL, Castillo-Carranza D, Sengupta U, Guerrero-Muñoz M, Kelly B, Wagner R, Kayed R. Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity. Biochem Biophys Res Commun. 2013 Jan 18;430(3):963-8. doi: 10.1016/j.bbrc.2012.11.130. PubMed PMID: 23261448. 
  17. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi T, Neugebauer V, Jackson GR, Kayed R. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep. 2012;2:700. doi: 10.1038/srep00700. PubMed PMID: 23050084; PubMed Central PMCID: PMC3463004. 
  18. Castillo-Carranza DL, Zhang Y, Guerrero-Muñoz MJ, Kayed R, Rincon-Limas DE, Fernandez-Funez P.Differential activation of the ER stress factor XBP1 by oligomeric assemblies. Neurochem Res. 2012 Aug;37(8):1707-17. doi: 10.1007/s11064-012-0780-7. PubMed PMID: 22528838; PubMed Central PMCID: PMC3387497. 
  19. Lasagna-Reeves C, Castillo-Carranza DL, Guerrero-Muñoz MJ, Jackson GR, Kayed R. Preparation and Characterization of Neurotoxic Tau Oligomers. Biochemistry 2010, 10039–10041. doi: 10.1021/bi1016233. (Most accessed research article in the first 30 days of its publication). PMID:21047142. 
  20. Martínez HR, González-González H, Cantú-Martínez L, Rangel-Guerra R, Hernández-Castillo CD, Vergara-Saavedra JJ, Ramos-Gonzalez MR, Cerda-Flores RM, Morales-Garza MA, Guerrero-Muñoz MJ, Montes-de-Oca-Luna R, Saucedo-Cárdenas O. PARKIN-coding polymorphisms are not associated with Parkinson's disease in a population from northeastern Mexico. Neurosci Lett. 2010 Jan 14;468(3):264-6. PMID:19909784. 
  21. Acuna-Askar K, de la Torre-Torres MA, Guerrero-Muñoz MJ, Garza Gonzalez MT, Chavez-Gomez B, Rodriguez-Sanchez IP and Barrera-Saldana HA. Biodegradation kinetics of BTE-OX and MTBE by a diesel-grown biomass.  Water Science & Technology.  Vol 53 No 11 pp 197–204 © IWA Publishing 2006. PMID: 16862790.